A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Condition(s) studied

Study summary

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases.

So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.

Eligibility

Primary outcome measure(s)

• seizure outcomes — 1 year, 2 year
  The incidence of different seizure outcomes and associated factors will be analyzed.
• Clinical severity and recovery 1 — 1 year, 2 year
  modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome
• Clinical severity and recovery 2 — 1 year, 2 year
  clinical assessment scale for autoimmune encephalitis, ranging from 0-27, higher scores mean a worse outcome
• Incidence of recurrence — 1 year, 2 year
  a relapse of encephalitis

Trial sites (1)

More Shen Chun-Hong trials in China

Other trials for the same condition